Clozapine rechallenge after clozapine-induced myocarditis: A case report to validate a previously published protocol

Abstract Introduction: Clozapine is an effective antipsychotic indicated for treatment-resistant schizophrenia (TRS). Its use is limited by its extensive adverse effect profile featuring rare but serious consequences like clozapine-induced myocarditis (CIM). In the event of CIM, clozapine is discontinued; however, there is often no effective alternative for TRS. In this case, a rechallenge of clozapine may be considered. However, there is no standardized protocol to guide clinicians in this process. Case Report: This report describes the case of a 28-year-old